BIOMAT Database Logo BIOMAT Database Logo

Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. 1994

M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
SmithKline Beecham Pharmaceuticals, Welwyn, Herts, UK.

Twenty healthy male volunteers received single oral doses of famciclovir (125-750 mg), in a randomized, single-blind, crossover study. Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis. Peak plasma concentrations of penciclovir were obtained at median times of 0.5-0.75 h after dosing. The areas under the concentration versus time curves (AUC) and the peak penciclovir concentration (Cmax) increased linearly with dose of famciclovir. Time to Cmax, elimination half-life, urinary recovery and renal clearance of penciclovir did not change with increasing dose. Famciclovir was excreted via the kidneys as penciclovir (60%) and BRL 42359 (5%), respectively. Famciclovir was well tolerated by all subjects with a low incidence of adverse effects. In conclusion, penciclovir thus displays linear pharmacokinetics in the anticipated therapeutic dose range of famciclovir.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006147 Guanine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077595 Famciclovir An aminopurine derivative and prodrug of penciclovir which is a competitive inhibitor of herpes simplex 2 DNA polymerase. It is used to treat HERPES SIMPLEX VIRUS INFECTION. 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester),9-(4-Acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine,BRL 42810,BRL-42810,Famvir,BRL42810
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses.
May 1998, Biopharmaceutics & drug disposition,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir.
July 2012, American journal of veterinary research,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats.
November 2007, American journal of veterinary research,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study.
September 2012, Veterinary ophthalmology,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses.
March 2010, The Journal of veterinary medical science,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers.
January 1991, Psychopharmacology,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses.
November 1992, Biopharmaceutics & drug disposition,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.
December 2012, International journal of clinical pharmacology and therapeutics,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Cephalexin concentrations in radicular granuloma following a single oral administration of 250- or 500-mg cephalexin.
December 1994, General pharmacology,
M A Pue, and S K Pratt, and A J Fairless, and S Fowles, and J Laroche, and P Georgiou, and W Prince
Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.
January 1995, Infection,
Copied contents to your clipboard!